Article contents
Galantamine beyond Alzheimer’s disease—a fact or artefact?
Published online by Cambridge University Press: 14 December 2020
Abstract
Galantamine is US-Food and Drug Administration FDA-approved for mild-to-moderate Alzheimer’s disease. However, its unique pharmacological portfolio speaks to the idea of a pluripotent agent with a broad therapeutic potential. Here, authors briefly discuss these off-label clinical indications synthesizing the extant evidence.
Keywords
- Type
- Perspective
- Information
- Copyright
- © The Author(s), 2020. Published by Cambridge University Press
References
- 3
- Cited by